Results from a PHASE2 study (NCT04624178) investigating Nivolumab in combination with Rucaparib for people with Leiomyosarcoma were posted on 2026-07-17. The trial, which enrolled 20 participants, reported a Best Objective Response Rate of 5 percentage of participants and a median Progression Free Survival of 7.8 weeks.
Background
This study investigated the combination of Rucaparib and Nivolumab as a potential treatment for advanced and/or metastatic Leiomyosarcoma (LMS).
Trial design
The study, identified as NCT04624178, was a PHASE2 trial that enrolled 20 participants with Leiomyosarcoma. The purpose was to evaluate the effectiveness of combining Rucaparib and Nivolumab for advanced and/or metastatic LMS.
Key results
The trial reported on the Best Objective Response Rate and Progression Free Survival (PFS) for the combination of Rucaparib and Nivolumab:
- The Best Objective Response Rate was observed in 5 percentage of participants.
- The median Progression Free Survival (PFS) was 7.8 weeks.
What this means
The results from this PHASE2 study provide initial efficacy data for the combination of Nivolumab and Rucaparib in individuals with Leiomyosarcoma. The observed objective response rate and median progression-free survival offer insights into the potential activity of this combination therapy in this patient population. Further evaluation would be needed to understand its role compared to existing treatments.
Source
This information was sourced from ClinicalTrials.gov, documenting the results of trial NCT04624178, which were posted on 2026-07-17. The study details are available on clinicaltrials.gov.